Patent · US Active

RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules

US9782357B2 · kind B2 · utility

1Cited by

0References

18Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

Yunfeng Lu · Los Angeles, US
Irvin S. Y. Chen · Rancho Palos Verdes, US
Ming Yan · Los Angeles, US
Min-Chang Liang · Baoshan, TW
Masakazu Kamata · Los Angeles, US
Jing Wen · Sudbury, US

Key dates

Filing date	Mar 15, 2013
Grant date	Oct 10, 2017
Priority date	—
Expiry date	Mar 15, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.